We are pleased to share an insightful article from Pharma Tech Outlook featuring Dipharma as a trusted CDMO and a partner of choice for companies seeking solid chemical development and manufacturing expertise. Our strategic approach combines flexibility, responsiveness, and transparency.
In the interview, Andrea Confetti, Exclusive Synthesis Business Unit Leader at Dipharma, explains how we prioritize customers, uphold the highest manufacturing quality standards, and provide end-to-end support throughout the entire lifecycle of a molecule.
As a third-generation, family-owned company, we are committed to long-term partnerships, delivering tailored solutions beyond standard CDMO services through dedicated projectmanagement and continuous strategic alignment.
We thank Pharma Tech Outlook for the opportunity to share our vision and values with the broader pharmaceutical community.
Read the full article on line: https://www.pharmatechoutlook.com/dipharma
For more information
Paola Clerici
Communication Manager
DIPHARMA FRANCIS S.r.l.
paola.clerici@dipharma.com
